When was ReNeuron Group founded?

ReNeuron Group was founded in 1997 and raised its 1st funding round 13 years after it was founded.

Where is ReNeuron Group located?

ReNeuron Group is headquartered in Guildford, United Kingdom.

How many employees does ReNeuron Group have?

As of Jul 31, 2026, the latest employee count at ReNeuron Group is 26.

Is ReNeuron Group a funded company?

ReNeuron Group is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 2010.

When was the latest funding round of ReNeuron Group?

ReNeuron Group's latest funding was a $***** Grant (prize money) round on Apr 19, 2018, with participation from 1 investor. Its primary sector is Neurology. In United Kingdom, the Neurology sector has seen $144M in funding in 2026 to date.

Where does ReNeuron Group rank among its competitors?

ReNeuron Group ranks 653rd amongst 3806 active competitors, of which 1275 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of ReNeuron Group?

ReNeuron Group's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

ReNeuron Group - 2026 Company Profile, Team, Funding, Competitors & Financials

ReNeuron Group is a public company based in Guildford (United Kingdom), founded in 1997. It operates as a Developer of stem-cell-based therapeutics for stroke disability and critical limb ischemia. ReNeuron Group has raised an undisclosed amount in funding. The company has 3806 active competitors, including 1275 funded and 902 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Developer of stem-cell-based therapeutics for stroke disability and critical limb ischemia. The company’s therapeutic product pipeline includes ReN001 for disabled stroke patients. Also, the company has other products which include human retinal progenitor cell therapy for retinitis pigmentosa, CTX cells for Parkinson's disease, and ischemic stroke.

Website: www.reneuron.com
Email ID: *****@reneuron.com

Key Metrics

Founded Year

1997

Location

Guildford, United Kingdom

Stage

Public

Latest Funding Round

Grant (prize money), Apr 19, 2018, $*****

Investors

Gov & 1 more

Ranked

653^rd among 3806 active competitors

Employee Count

26 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3588 more

Exit Details

Public

View ReNeuron Group's full profile

ReNeuron Group is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
RENEURON GROUP PLC CIN: 5474163 , Germany, Active	Jun 06, 2005	-	34 (As on Mar 31, 202022)

ReNeuron Group got listed on Aug 12, 2005.

Click here to take a look at ReNeuron Group's IPO in detail

ReNeuron Group has raised funding over 7 rounds. Its first funding round was on Feb 2010. Its latest funding round was a Grant (prize money) round on Apr 19, 2018 for $*****. 1 investor participated in its latest round. ReNeuron Group has 2 institutional investors.

Here is the list of recent funding rounds of ReNeuron Group:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 19, 2018	9430973	Grant (prize money)	4818819	2106386	5105500	8642409
May 11, 2017	5518453	Grant (prize money)	2780896	4915834	6623929	Gov
Aug 2015	1850274	Post IPO	6088681	3767140	9201997	3780420

Access funding benchmarks and valuations. Sign up today!

View details of ReNeuron Group's funding rounds and investors

ReNeuron Group's employee count trend

ReNeuron Group has 26 employees as of Jul 26. Here is ReNeuron Group's employee count trend over the years:

Uncover ReNeuron Group's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ReNeuron Group include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of ReNeuron Group, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
653rd	ReNeuron Group 1997, Guildford (United Kingdom), Public	Developer of stem-cell-based therapeutics for stroke disability and critical limb ischemia	-	Gov, Seneca Growth Capital	51/100